Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension
| Autor: | Monique Klaver, T. Drogendijk, Roman Sokol, Matthias Oelke, Klaudia Traudtner, Christopher R. Chapple, Philip Van Kerrebroeck, Marcus J. Drake |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Solifenacin Succinate
Male Tamsulosin medicine.medical_specialty Time Factors Urology media_common.quotation_subject Chemistry Pharmaceutical Urinary Bladder Prostatic Hyperplasia Administration Oral Muscarinic Antagonists Urination Double-Blind Method Lower Urinary Tract Symptoms Lower urinary tract symptoms medicine Humans media_common Aged Aged 80 and over Sulfonamides Solifenacin Urinary retention business.industry Urinary Bladder Overactive Middle Aged Urinary Retention medicine.disease Drug Combinations Urodynamics Treatment Outcome Adrenergic alpha-1 Receptor Antagonists Urological Agents International Prostate Symptom Score medicine.symptom business Tamsulosin hydrochloride medicine.drug Tablets |
| Zdroj: | European urology. 67(2) |
| ISSN: | 1873-7560 |
| Popis: | Background Short-term trials have demonstrated the efficacy and safety of combination therapy using antimuscarinics and α-blockers in men with lower urinary tract symptoms (LUTS). The Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS (oral controlled absorption system) in Males with Lower Urinary Tract Symptoms (NEPTUNE) II is the first long-term study using solifenacin (Soli) and the oral controlled absorption system formulation of tamsulosin (TOCAS). Objective To evaluate long-term (up to 52 wk) safety and efficacy of flexible dosing of two fixed-dose combinations (FDC) of Soli plus TOCAS in men with moderate to severe storage symptoms and voiding symptoms. Design, setting, and participants Patients with both storage and voiding LUTS, maximum urinary flow rate of 4.0–12.0ml/s, prostate size Intervention FDC of Soli 6mg plus TOCAS 0.4mg, or Soli 9mg plus TOCAS 0.4mg; patients could switch between doses in NEPTUNE II. Outcome measurements and statistical analysis Safety and efficacy data from NEPTUNE and NEPTUNE II were combined to cover a 52-wk period. Primary efficacy end points were total International Prostate Symptom Score (IPSS) and total urgency and frequency score (TUFS); secondary end points included IPSS storage and voiding subscores, micturition diary variables, and quality of life parameters. Results In all, 1066 men completed NEPTUNE and received one dose or more of study medication in NEPTUNE II. Treatment-emergent adverse events were reported in 499 (46.8%) patients who participated in NEPTUNE II; most were mild or moderate. Urinary retention occurred in 13 of 1208 (1.1%) patients receiving one or more FDCs in NEPTUNE and/or NEPTUNE II; 8 (0.7%) required catheterisation (acute urinary retention [AUR]). Reductions in total IPSS and TUFS during NEPTUNE were maintained for up to 52 wk of FDC treatment, with mean reductions of 9.0 (standard deviation [SD]: 5.7) and 10.1 (SD: 9.2), respectively, from baseline to end of treatment. Clinically relevant improvements were also observed for secondary efficacy end points. Conclusions Long-term treatment with FDC Soli plus TOCAS was well tolerated and efficacious in men with storage and voiding LUTS, with a low incidence of AUR. Patient summary Treatment with solifenacin plus tamsulosin in a fixed-dose combination tablet was well tolerated by men with lower urinary tract symptoms. Improvements in symptoms were achieved after 4 wk of treatment, with further improvements at week 16 maintained for up to 52 wk throughout the study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect